Certificate under SEBI Regulations for Quarter Ended 30th September 2025
Eris Lifesciences Limited submits a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2025, confirming the dematerialization of securities.
This is a standard compliance filing and does not have a significant impact on the company's operations or stock value.
The announcement is a routine compliance disclosure, providing factual information without expressing opinions or forward-looking statements.
* Eris Lifesciences Limited submits a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. * The certificate pertains to the quarter ended 30th September 2025. * It confirms the dematerialization of securities during the quarter. * The certificate is received from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent (RTA).
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.